Evidence map›Paper›PMID 35505017›Full record

ArticleMethods in molecular biology (Clifton, N.J.)2022

Orthotopic Models of Pancreatic Cancer to Study PDT.

Girgis Obaid, Zhiming Mai, Tayyaba Hasan

Open access · greenAbstract read
In one paragraph

Article in Methods in molecular biology (Clifton, N.J.), 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
1.9field-weighted citation impact, top 15% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed, 3 citations in OpenAlex.

  1. Clinical application and drug resistance mechanism of gemcitabine.Frontiers in cell and developmental biology · 2025
    Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

3 authors at 2 institutions in 1 country.

Girgis Obaid *Department of Dermatology, Massachusetts General Hospital, Harvard Medical School, Wellman Center for Photomedicine, Boston, MA, USA.
Zhiming Mai *Department of Dermatology, Massachusetts General Hospital, Harvard Medical School, Wellman Center for Photomedicine, Boston, MA, USA.
Tayyaba HasanDepartment of Dermatology, Massachusetts General Hospital, Harvard Medical School, Wellman Center for Photomedicine, Boston, MA, USA. thasan@mgh.harvard.edu.
Massachusetts General Hospital · USHarvard University · US

Funding

Small Molecule Enhancers of Photodynamic Therapy for Skin CancerP01CA084203 · NCI · MASSACHUSETTS GENERAL HOSPITAL · PI Tayyaba Hasan · 2001 to 2026
$27.9M
Molecular imaging-directed bioengineering of nanoconjugates as adaptable tumor targeting platformsR00CA215301 · NCI · UNIVERSITY OF TEXAS DALLAS · PI OBAID, GIRGIS · 2020 to 2022
$721k
Molecular imaging-directed bioengineering of nanoconjugates as adaptable tumor targeting platformsK99CA215301 · NCI · MASSACHUSETTS GENERAL HOSPITAL · PI OBAID, GIRGIS · 2018 to 2019
$358k
NCI NIH HHS K99 CA215301NCI NIH HHS P01 CA084203NCI NIH HHS R00 CA215301
6 · The paper itself

Abstract

A hallmark of pancreatic ductal adenocarcinoma (PDAC) is its poor prognosis that stems from a marked resistance to therapy, an invasive nature, and a high metastatic potential. Photodynamic therapy (PDT) is a promising modality for effectively managing PDAC both preclinically and clinically. While clinical trials of PDT for PDAC are still in their early stages, a plethora of elegant preclinical studies are supporting the translation and clinical adoption of PDT-based treatment regimens, many of which leverage orthotopic preclinical models of PDAC. Given the aggressiveness of the disease that is largely dependent on the localization of PDAC tumors, it is imperative that preclinical models used to evaluate PDT-based treatment regimens recapitulate elements of the natural pathogenesis in order to design treatment regimens tailored to PDAC with the highest potential for clinical success. In light of the importance of clinically relevant models of PDAC, this chapter details and discusses the methodologies developed over the last three decades to leverage orthotopic PDAC models in order to evaluate PDT-based treatment regimens. The shortcomings of these are also discussed, in addition to the future directions that the field is headed to establish the most relevant orthotopic models of PDAC.

Indexed as

Carcinoma, Pancreatic DuctalPancreatic NeoplasmsPhotochemotherapyHumansOrthotopic modelsPancreatic ductal adenocarcinomaPhotodynamic therapy

Identifiers

PMID35505017
PMCPMC10515273
OpenAlexW4285266622

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.